தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ Today - Breaking & Trending Today

'Obesity Paradox' in Kidney Cancer Continues in Checkpoint Inhibitor Era

email article
Elevated BMI was tied to improved survival in metastatic renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors, a retrospective study found.
In the analysis of more than 700 metastatic RCC patients who received PD-1/L1 immunotherapies, those with a BMI of 25 or greater had significantly longer overall survival (OS), with 1-year rates of 79% versus 66% for those with a BMI below that cutoff (HR 0.75, 95% CI 0.57-0.97,
P=0.03), Toni Choueiri, MD, of Dana-Farber Cancer Institute in Boston, and colleagues reported.
These findings are consistent with the obesity paradox that was previously seen during the VEGF-targeted therapy era, the group wrote in ....

United States , Dana Farber Cancer Institute , Toni Choueiri , Ian Ingram , International Metastatic , Database Consortium , Medpage Today , Deputy Managing Editor , Clear Cell Carcinoma Of Kidney , Malignant Tumor Of Kidney , Neoplasm Of Kidney , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , ஈயந் இஂக்ரம் , சர்வதேச மெட்டாஸ்டேடிக் , தரவுத்தளம் கூட்டமைப்பு , துணை நிர்வகித்தல் ஆசிரியர் , தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ , வீரியம் மிக்கது கட்டி ஆஃப் கிட்நீ , உடல் பருமன் ,

'A Demand That Utterly Outstrips the Supply': What We Heard This Week

email article
That s a demand that utterly outstrips the supply that we have. Jim Jackson, PsyD, of Vanderbilt University Medical Center in Nashville, on a study suggesting that many COVID survivors have post-traumatic stress disorder.
It s like taking a football and shoving it into a pipe with the diameter of a golf ball. David Nauen, MD, PhD, of Johns Hopkins University in Baltimore, about the unexpected presence of megakaryocytes in the brain capillaries of people who died with COVID-19.
This is one of those findings where you can hear it at [the Genitourinary Cancers Symposium] and take it to the clinic on Monday. Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California, discussing a new option for a rare type of kidney cancer. ....

New York , United States , Jim Jackson , Mark Collins , Sumanta Pal , David Nauen , Johns Hopkins University In Baltimore , Vanderbilt University Medical Center , Icahn School Of Medicine At Mount Sinai , University Of California Berkeley , City Of Hope Comprehensive Cancer Center , Johns Hopkins University , Hope Comprehensive Cancer Center , California Berkeley , Icahn School , Mount Sinai , New York City , Clear Cell Carcinoma Of Kidney , Renal Mass , Neoplasm Of Pelvis , Neoplasm Of Kidney , Malignant Neoplastic Disease , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஜிம் ஜாக்சன் , குறி கோலின்ஸ் ,

New First-Line Kidney Cancer Combination Gets FDA Nod

email article
Support for approval came from CheckMate-9ER, a phase III trial that randomized 651 previously untreated patients with advanced RCC to either sunitinib (Sutent) alone or the combination of nivolumab, a PD-1-directed checkpoint inhibitor, plus the tyrosine kinase inhibitor cabozantinib, until disease progression or unacceptable toxicity.
This combination of cabozantinib and nivolumab significantly improved key efficacy measures compared to sunitinib progression-free survival, overall survival, and objective response rate while showing a low rate of treatment discontinuations due to side effects, investigator Toni Choueiri, MD, of Dana-Farber Cancer Institute in Boston, said in a statement.
Overall survival was significantly improved with nivolumab (240 mg every 2 weeks delivered intravenously) plus oral cabozantinib (40 mg daily) compared with oral sunitinib at standard dosing, with a median not reached in either study arm (HR 0.60, 95% CI ....

United States , Dana Farber Cancer Institute , Toni Choueiri , Ian Ingram , Medpage Today , Deputy Managing Editor , Clear Cell Carcinoma Of Kidney , Renal Mass , Malignant Tumor Of Kidney , Neoplasm Of Kidney , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , ஈயந் இஂக்ரம் , துணை நிர்வகித்தல் ஆசிரியர் , தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ , சிறுநீரகம் நிறை , வீரியம் மிக்கது கட்டி ஆஃப் கிட்நீ ,